The unstructured domain of colicin N kills <em>Escherichia coli</em> by Johnson CL et al.
 Newcastle University ePrints 
 
Johnson CL, Ridley H, Pengelly RJ, Salleh MZ, Lakey JH.  
The unstructured domain of colicin N kills Escherichia coli.  
Molecular Microbiology 2013, 89(1), 84-95. 
 
Copyright: 
© 2013 The Authors. Molecular Microbiology published by John Wiley & Sons Ltd. 
This is an open access article under the terms of the Creative Commons Attribution License, which 
permits use, distribution and reproduction in any medium, provided the original work is properly cited. 
DOI link to article: 
http://dx.doi.org/10.1111/mmi.12260 
Date deposited:  20th March 2014 
 
 
 
This work is licensed under a Creative Commons Attribution 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
The unstructured domain of colicin N kills Escherichia coli
Christopher L. Johnson, Helen Ridley,
Robert J. Pengelly, Mohd Zulkifli Salleh and
Jeremy H. Lakey*
Centre for Bacterial Cell Biology, Institute for Cell and
Molecular Biosciences, Faculty of Medical Sciences,
Newcastle University, Framlington Place, Newcastle-
upon-Tyne NE2 4HH, UK.
Summary
Bacteria often produce toxins which kill competing
bacteria. Colicins, produced by and toxic to Escheri-
chia coli bacteria are three-domain proteins so effi-
cient that one molecule can kill a cell. The C-terminal
domain carries the lethal activity and the central
domain is required for surface receptor binding. The
N-terminal domain, required for translocation across
the outer membrane, is always intrinsically unstruc-
tured. It has always been assumed therefore that
the C-terminal cytotoxic domain is required for the
bactericidal activity. Here we report the unexpected
finding that in isolation, the 90-residue unstructured
N-terminal domain of colicin N is cytotoxic. Further-
more it causes ion leakage from cells but, unlike
known antimicrobial peptides (AMPs) with this prop-
erty, shows no membrane binding behaviour. Finally,
its activity remains strictly dependent upon the same
receptor proteins (OmpF and TolA) used by full-length
colicin N. This mechanism of rapid membrane dis-
ruption, via receptor mediated binding of a soluble
peptide, may reveal a new target for the development
of highly specific antibacterials.
Introduction
For many years the structure–function paradigm governed
our view of protein biochemistry until in the last decade
it became clear that intrinsically unstructured domains
(IUDs) are critical to many processes. IUDs are most com-
monly involved in protein–protein interactions; however,
they are also involved in protein–DNA and protein–RNA
binding. Their inherent disorder is fundamental to their
biological roles. The intrinsic flexibility of IUDs confers
several functional advantages, such as specificity without
excessive binding strength, increased speed of interaction
and binding promiscuity making IUDs ideal for signalling
and regulatory processes (Meszaros et al., 2011). Thus
they are implicated in transcription, translation and cell
signalling in all three domains of life and conservative
estimates indicate at least 25% of sequences in SwissProt
contain long disordered regions (Romero et al., 2001).
One of the best-studied examples of a protein with IUDs,
the crucial tumour suppressor protein p53, exhibits a highly
biased use of disordered regions for mediating and modu-
lating interactions with other proteins, utilizing different
regions in the disordered tails to enable binding to multiple
partners’ simultaneously (Oldfield et al., 2008). Here we
add antibacterial activity to their list of roles and interest-
ingly this newly discovered function also relies upon the
ability to bind two different proteins.
The appearance of antibiotic-resistant and novel patho-
genic strains of Escherichia coli (E. coli) emphasizes the
continuing need for new antibacterial treatments. AMPs
are produced by a wide variety of living organisms from
bacteria to animals and are a potentially large antibiotic
resource (Melo et al., 2009). They often kill bacteria by
membrane disruption which is a highly effective and rapid
mechanism. However, since human and bacterial mem-
branes are similar; it is often difficult to target only the
bacteria and avoid damage to the patient’s cells. Thus in
order to viably use membrane disrupting molecules in
antibacterial chemotherapy their specificity needs to be
improved.
Bacteria often compete among themselves for
resources and this selection pressure has encouraged the
widespread evolution of antibacterial behaviour in bacte-
ria. Often this involves the secretion of antibacterial
molecules into the shared extracellular space leading to
inhibition or death of the competitor cells. These antibac-
terial proteins are collectively called bacteriocins and
include peptides (e.g. nisin), small proteins (e.g. pediocins)
and larger proteins such as the pyocins (Pseudomonas)
and pesticins (Yersinia pestis). Unlike traditional antibiot-
ics, bacteriocins are often only toxic to bacteria closely
related to the producing strain (Riley and Wertz, 2002).
Escherichia coli produces two classes of bacteriocins
(Gordon and O’Brien, 2006) which are typically plasmid
encoded. These are the low-molecular-weight microcins
and the larger (> 30 kDa) colicins. Microcins range from 1
to 10 kDa and have minimum inhibitory concentrations
(MICs) in the nanomolar range. They disrupt a wide range
of functions in the target cell including ATP synthetase
(Rodriguez and Lavina, 2003) and DNA gyrase (Heddle
et al., 2001). In general, translocation of microcins into the
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target cell requires proteins of the Ton system (Duquesne
et al., 2007) which normally import low abundance nutri-
ents. The Ton system comprises an outer membrane
receptor (e.g. Cir), the periplasm-spanning TonB protein
and two inner membrane proteins, ExbB and ExbD. Some
microcins imitate the structures of nutrients and this may
define their uptake pathway (Strahsburger et al., 2005).
Colicins range in size from 30 to 80 kDa and are
extremely efficient toxins with MICs in the pM–nM range;
requiring only one molecule to kill a target cell. They play
an important role in gut colonization by new strains and
have varied killing mechanisms which include pore-
formation, DNase or RNase activity or inhibition of pepti-
doglycan biosynthesis (Cascales et al., 2007). Some
colicins (Group B) exploit the Ton system but others
(Group A) hijack the Tol protein system (TolA, TolB, TolQ
and TolR) (Cascales et al., 2007) which is unexploited by
microcins. TolA resembles TonB, spans the periplasm and
is coupled to the proton motive force but, unlike TonB, is
not linked to nutrient transport. Rather, TolA is implicated
in outer membrane stability and cell division (Gerding
et al., 2007).
Regardless of the mechanism of import, all colicins have
the same modular three-domain structure; an N-terminal
translocation (T) domain, a central receptor binding (R)
domain and a C-terminal cytotoxic domain which carries
the lethal activity (Braun et al., 2002). In every colicin the
N-terminal T-domain contains an IUD with no defined 3D
structure. These IUDs contain the TolA, TolB and TonB
binding regions and join a growing list of IUDs which have
been shown to play key roles in molecular recognition, cell
regulation and disease in all proteomes (Dunker and
Kriwacki, 2011). C-terminal domains vary in structure
according to function and it is possible to exchange
the toxic activity of a colicin (e.g. pore-former to DNase)
by swapping the C-terminal domain for another type
(Benedetti et al., 1991). Thus while the C-terminus con-
tains and determines the toxic function, the remaining two
domains are traditionally viewed as the vehicle which
efficiently transports the toxicity into the cell.
Most colicins use two different types of outer membrane
receptors, e.g. in ‘E’ colicins the high-affinity receptor,
BtuB, is recognized by the tip of the coiled-coil R-domain
(Penfold et al., 2004; Sharma et al., 2007). The secondary
receptor, or translocator, OmpF is then recruited by the IUD
T-domain (Housden et al., 2005; 2011). Other colicins
require only one type of outer membrane receptor and here
the best-studied example is ColIa (Buchanan et al., 2007;
Udho et al., 2009). Crucially for the work reported here it
has recently been demonstrated that ColIa requires two
copies of its receptor Cir; one for reception and one for
translocation (Jakes and Finkelstein, 2010).
Colicin N (ColN), which we study, is a colicin which
requires a single type of outer membrane protein, OmpF.
As with all colicins it has always been assumed that
the sole role of the ColN T-domain (Pugsley, 1987;
Bourdineaud et al., 1990; Fourel et al., 1990; El Kouhen
et al., 1993; El Kouhen and Pages, 1996) was to deliver
the cytotoxic C-terminal domain across the outer mem-
brane (Kleanthous, 2010). Here we report the unexpected
finding that the isolated unstructured T-domain of ColN
kills E. coli in an OmpF and TolAQR-dependent manner.
This is the first example of bactericidal membrane disrup-
tion by an IUD. Furthermore, we also show that (like
ColIa) ColN hijacks two copies of its outer membrane
receptor during translocation.
Results
The cytotoxic C-terminal pore-forming domain of ColN is
dispensable for antimicrobial activity
When using a simple spot test assay to screen ColN
deletion mutants, we found that the pore-forming domain of
ColN (ColN-P) was dispensable for antimicrobial activity.
Both the T- and R-domains combined (ColN-TR) and the
T-domain in isolation (ColN-T) produced zones of clearing
(Fig. 1A) when applied to a lawn of E. coli, the same
feature observed with ColN (e.g. ColN-TRP). ColN showed
killing activity when as little as 6 ng of protein was added to
the lawn of E. coli, ColN-TR needed 60 ng and ColN-T
600 ng. Additionally, we observed a halo when spotting
ColN-TR at its highest concentration (6000 ng). The halo
represents live cells in the centre of the spot and a zone of
clearing at the periphery. This suggests ColN-TR displays
self-inhibition of killing in the centre of the spot where the
concentration of ColN-TR is at its highest, a phenomenon
also seen with ColIa (Jakes and Finkelstein, 2010).
ColN-TR and ColN-T are potent antimicrobials which
display unique specificity
We next addressed the cytotoxic activity of ColN-TR and
ColN-T. K+ efflux assays are an extremely sensitive quan-
titative assay of ColN activity, measuring the real-time
release of intracellular K+ from E. coli. These revealed that
both ColN-TR and ColN-T provoked K+ efflux from cells,
albeit less efficiently than ColN (Fig. 1B). This trend was
repeated in the MICs (Fig. 2). ColN was found to have
a MIC of 1 nM, a result anticipated from the literature
(Sharma et al., 2009). ColN-TR and ColN-T were found to
have MICs of 100 nM and 10 μM respectively which are
comparable to known AMPs (Melo et al., 2009). To test the
specificity of this newly discovered antimicrobial activity,
spot test assays against E. coli cells lacking either OmpF
or TolA were carried out. In each case, ColN-TR and
ColN-T are non-toxic (Fig. S1A and B) and thus, like full-
length ColN, they are strictly dependent upon both OmpF
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and TolA. ColIa was used as a positive control since it relies
upon Cir and TonB and therefore has no requirement for
OmpF or TolA. ColIa not only produced zones of clearing in
the absence of either OmpF or TolA, but also showed the
previously described halo of self-inhibition (Jakes and
Finkelstein, 2010). ColN binds TolA directly but its activity
also depends upon the whole inner membrane complex
TolAQR (Sharma et al., 2009). The susceptibility of ΔtolQ
(tolQ786::kan) and ΔtolR (tolR787::kan) strains to ColN,
ColN-TR and ColN-T was tested, alongside the wild-type
Keio strain BW25113 [rrnB3 ΔlacZ4787 hsdR514
Δ(araBAD)567 Δ(rhaBAD)568] (Baba et al., 2006)
(Fig. S1C–E). BW25113 showed susceptibility to all three
constructs as would be expected for a wild-type strain
(Fig. S1A). Both ΔtolQ and ΔtolR strains showed expected
partial resistance to ColN but complete resistance to both
ColN-TR and ColN-T (Fig. S1D and E). This demonstrates
that the entire TolAQR inner membrane complex is essen-
tial for killing by ColN-TR or ColN-T. TolB on the other hand
is not required for toxicity by ColN, ColN-T or ColN-TR
(results not shown).
Isolation of an OmpF binding site in ColN-T
The OmpF dependence of ColN-T correlates with the
recent demonstration of two OmpF binding sites within
ColE9-T (Housden et al., 2011). Short regions of predicted
order bounded by extended regions of predicted disorder
(predicted using PONDR VL-XT) have been shown in
several cases to identify binding sites that undergo
disorder-to-order transitions upon complex formation
(Garner et al., 1998), with the disorder-to-helix transition
being particularly common (Fuxreiter et al., 2004). PONDR
analysis (Romero et al., 1997; 2001; Garner et al., 1998; Li
et al., 1999; Fuxreiter et al., 2004) predicted an ordered
region within the IUD spanning residues 8–15 (Hecht et al.,
2009). This region was tentatively termed OBS1 [OmpF
binding site 1 (Housden et al., 2011)]
Next we carried out multiple sequence alignments of
ColN against other colicins which use OmpF for import
(Fig. S2A and B). Alignment of ColN-T with the OmpF-
dependent pore-forming colicins; colicin K (ColK) and
colicin A (ColA) reveals low homology in the ColN OBS1
Fig. 1. Comparing of ColN, ColN-TR and ColN-T activity.
A. Spot test assay to demonstrate killing of E. coli cells by colicin constructs which lack the P-domain. Two microlitre volumes corresponding
to 6000 ng, 600 ng, 60 ng and 6 ng of ColN, ColN-TR and ColN-T were spotted onto a lawn of E. coli. As a negative control 2 μl of the buffer
in which the colicins were diluted (50 mM sodium phosphate, pH 7.5, 300 mM NaCl) was spotted (x).
B. K+ efflux assay to compare the activity of ColN added at 600 molecules per cell (mpc) (green), ColN-TR added at 105 mpc (red), ColN-T
added at 2 × 105 mpc (blue) compared with a negative control to which no colicin is added to cells (black).
Fig. 2. Schematic of ColN domain mutants
used in this work and their associated
minimum inhibitory concentrations (MICs) and
OmpF/TolA dependencies. NA: not active in
the range 1 pM–10 μM. ND: not determined.
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region with only loose conservation of glycine residues, as
expected in such glycine-rich IUDs. We next aligned ColN
with the known OBS1 and 2 sites of ColE9. This reveals
little similarity to either OBS1 or OBS2 regions; however,
the di-peptide sequence of (His)-(Asn) is conserved in
ColE9, ColE3 and ColN. PONDR analysis of the colicins
used in the multiple alignments (Fig. S3A) revealed that
the N-terminal ∼ 10 aa of colicin A (ColA) are predicted to
form an ordered region which encompasses the region
that aligns with the ColN OBS1 site (Fig. S2A). PONDR
analysis of the enzymatic colicins ColE9 and ColE3 pre-
dicted no ordered regions coincidental with OBS1 and
OBS2 sites of ColE9 (Fig. S3).
To experimentally test the role of OBS1 in OmpF binding
we mutated the region (N8AHNNAFG15 to N8GGSGGS G15)
(Fig. 3A) to generate ColNOBS1, ColN-TROBS1 and ColN-
TOBS1 respectively. ColNOBS1 provoked K+ efflux which
was only modestly slower than ColN (Fig. 3B). However
ColN-TROBS1 and ColN-TOBS1 were completely inactive
(Fig. 3C and D). Histidine 10 (H10) and phenylalanine 14
(F14) contribute the only large amino acid side-chains
in OBS1 so we made the point mutants ColNH10G and
ColNF14G. ColNH10G was less active than ColN but more
active than ColNOBS1 (Fig. S4A) while ColNF14G displayed
activity which overlaid with ColNOBS1 (Fig. 3E), demonstrat-
ing that F14 is a critical residue in OBS1. We also assessed
the activity of ColN missing the N-terminal 40 residues
ColN(41–387) (Fig. S4B) which removes OBS1 but leaves the
TolA binding site intact. The K+ efflux of ColN(41–387) was
found to be more rapid than ColNOBS1 (Fig. S4B). This
small increase may be due to the residual N-terminus of
ColNOBS1 forming unproductive interactions with OmpF. We
next used spot test assays and MIC tests. Spot test assays
failed to detect any difference in activity between ColNOBS1,
ColNF14G and ColNH10G (Fig. S5), while the more sensitive
MIC test did detect differences in their activities (Table S1).
Fig. 3. K+ efflux assays of OBS1 mutants in ColN, ColN-TR and ColN-T.
A. Sequence of the first 69 amino acids of ColN highlighting the OBS1 mutation (red box) and F14 (black star); NB: the complete OBS1 site is
yet to be defined.
B. ColN (green) and ColNOBS1 (red) added at 600 mpc, negative control (black).
C. ColN-TR (green) and ColN-TROBS1 (red) added at 105 mpc, negative control (black).
D. ColN-T (green) and ColN-TOBS1 (red) added at 2 × 105 mpc, negative control (black).
E. A direct comparison of the K+ efflux induced by ColNOBS1 (red) and ColNF14G (blue) added at 600 mpc. ColN (green) added at 600 mpc is
shown for reference, negative control (black).
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The MIC value obtained for ColNOBS1 and ColNF14G was
10 nM while that of ColNH10G was found to be 1 nM, the
same as ColN. In summary, this newly identified OmpF
binding site within ColN-T is essential for the toxicity of both
ColN-TR and ColN-T; however, its loss can be tolerated in
full-length ColN with only a modest reduction in activity.
Since both the OBS1 site and the TolA interaction are
essential for toxicity we produced a colicin construct
consisting of residues 1–69 with a C-terminal His tag
(ColN-T(1–69)) encompassing OmpF and TolAbinding boxes
and removing residues 70–90 to which no function has yet
been assigned. The activity of ColN-T(1–69) was compared
with ColN-T (i.e. 1–90) by K+ efflux. ColN-T(1–69) provoked
very similar K+ efflux to ColN-T (Fig. S4D).
OBS1 is essential for OmpF binding in vitro
Next, we wished to show that the loss of K+ efflux activity
in ColN-TROBS1 and ColN-TOBS1 was due to disruption of
OmpF binding. To do this we probed the binding of ColN,
ColN-TR, ColN-T, ColNOBS1, ColN-TROBS1 and ColNF14G to
OmpF using isothermal titration calorimetry (ITC). ColN,
ColN-TR and ColN-T all bound to OmpF with similar affini-
ties, demonstrating that it is ColN-T which drives OmpF
binding under these conditions (Table 1). The thermody-
namic parameters (negative TΔS) are consistent with the
disordered T-domain becoming ordered upon complex
formation.
Remarkably, the OBS1 mutation in ColNOBS1, ColN-
TROBS1 completely abolished OmpF binding. Presumably
OmpF binding would also be abolished in ColN-TOBS1;
however, since ColN-TOBS1 is unstable and we could not
produce sufficient quantities for ITC, this experiment
was not carried out. Finally we probed the interaction of
the single point mutant ColNF14G with OmpF. As with
the longer OBS1 mutation, this single point mutation
completely abolished OmpF binding. In summary these
results demonstrate the OmpF binding site in ColN-T
overlaps OBS1 and further support the role of F14 as a
critical residue in OBS1.
ColNOBS1 mutant activity is easily blocked by
non-functional ColNΔTolA mutants
ColNΔTolA (lacking residues 40–69) which retains functional
OBS1 site but no TolA (periplasmic receptor) binding ability
appears to form a stalled complex in the colicin translocon.
Experiments revealed that it partially blocks the activity of
ColN; when added at 3 × 105 molecules per cell (mpc) it
brought about a ∼ 50% reduction in K+ efflux (Fig. 4A). The
requirement for high multiplicities implies that ColNΔTolA is
inhibiting ColN at the OmpF binding stage (∼ 105 OmpF
molecules per cell). Significantly, although ColNOBS1 and
ColNF14G were completely blocked by the same amount of
ColNΔTolA, ColN(41–387) could partially overcome ColNΔTolA
blocking (Fig. 4B), but not as effectively as full-length ColN.
ColN-RP blocked ColN activity much less than ColNΔTolA;
however, this ‘ΔOBS1 + ΔTolA’ mutant still blocked signifi-
cantly against ColNF14G (Fig. 4C) and ColNOBS1 (Fig. 4D).
Finally ColN(41–387) overcame ColN-RP blocking signifi-
cantly better than proteins with simple mutations in the
OBS1 site (Fig. 4D). Thus ColNΔTolA and ColN-RP fully
block the action of ColN OBS1 mutants but cannot entirely
block full-length ColN or ColN(41–387).
ColN-T shows no evidence of membrane interactions
Since ColN-T provoked K+ leakage from cells, it appeared
likely that ColN-T was acting like pore-forming AMPs, of
which many have been described (Brogden, 2005). AMPs
can be unfolded in solution but fold on contact with lipid
membranes, disrupting the inner membrane by the forma-
tion of structured pores, although some may go on to
attack other intracellular targets. To discover whether
ColN-T was an AMP able to disrupt the inner membrane,
we assessed its interaction with model membranes.
Fluorescence experiments (Fig. 5A) showed no shift in
the ColN-T tryptophan spectrum in the presence of E. coli
lipid liposomes demonstrating that ColN-T does not
readily interact with E. coli phospholipids. In the presence
of SDS, circular dichroism experiments (Fig. 5B) showed
no formation of alpha helix structure, characteristic of
Table 1. Thermodynamic analysis of the binding of colicin mutants to OmpF.
Kd, μM N ΔH, kcal mol−1 TΔS, kcal mol−1 ΔG, kcal mol−1 Source
ColN 2.10 ± 0.70 2.40 ± 0.20 −12.31 ± 2.01 −4.54 ± 2.13 −7.74 ± 0.17 Evans et al. (1996a)
ColN-TR 1.60 ± 0.18 2.76 ± 0.01 −17.29 ± 1.58 −9.37 ± 1.65 −7.92 ± 0.07 This study
ColN-T 3.48 ± 0.03 2.29 ± 0.03 −19.09 ± 0.37 −11.62 ± 0.39 −7.46 ± 0.02 This study
ColNOBS1 NB NB NB NB NB This study
ColN-TROBS1 NB NB NB NB NB This study
ColNF14G NB NB NB NB NB This study
ITC parameters for the binding of ColN, ColN-TR, ColN-T, ColNOBS1 ColN-TROBS1 and ColNF14G to OmpF trimers at 25°C in 20 mM potassium
phosphate, pH 7.5, 150 mM NaCl, 1% Octyl-poe. The errors shown are those from duplicate experiments. NB: no binding (heats of interaction are
no greater than heats of dilution).
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many pore-forming peptides. This suggests that ColN-T
does not behave like other AMPs and remains as an
unstructured peptide in the presence of membranes. We
next prepared natural E. coli lipid liposomes filled with KCl
and assessed the ability of ColN-T to cause K+ leakage.
Under these conditions the loss of K+ from the liposomes
when ColN-T was added at 1 μM was the same as the
negative control of liposomes to which nothing was
added. However, melittin, used as a positive control pro-
voked significant K+ leakage at both 1 μM and 10 μM
(Fig. 5C). ColN-T thus requires additional factors to
disrupt the membrane such as protein receptors and/or an
energized membrane.
ColN-TR displays self-inhibition at high concentrations
ColN-TR self-inhibition at high concentrations, as exhib-
ited on spot test assays (Fig. 1A), was further investigated
using the more quantitative K+ efflux assay. ColN-TR and
ColN-T were added to E. coli cells at levels ranging from
104 to 6 × 105 molecules per cell (mpc) (Fig. 6A). The rate
of K+ efflux induced by ColN-T increased steadily with
concentration but below 105 mpc ColN-TR is a more effi-
cient killer than ColN-T, the rate of K+ efflux being at least
double that of ColN-T. However ColN-TR, showed a dis-
tinct optimum at 105 mpc after which the rate decreased
such that 6 × 105 mpc provided approximately the same
rate of efflux as 104 mpc. This decrease in rate suggests
that the R-domain is causing self-inhibition of T-domain
killing.
Removal of the R-domain (ColN-TP) also results in a
toxic protein. K+ efflux experiments revealed that ColN-TP
provoked K+ efflux at a similar rate to ColN-TR (non-self-
inhibiting multiplicity) of 2.5 × 104 mpc (Fig. 6B). ColN-TP
did not show self-inhibition (results not shown) indicating
a more specific role of the R-domain in OmpF binding.
Fig. 4. K+ efflux assays to assess the blocking of OBS1 mutants by ColNΔTolA (A and B) and ColN-RP (C and D).
A. ColN (green) was added at 600 mpc at 120 s as an unblocked control. For all other blocking runs ColNΔTolA was added after 60 s at
increasing multiplicities (orange = 104, yellow = 105, red = 1.3 × 105, blue = 1.6 × 105, magenta = 2 × 105, purple = 3 × 105 mpc) followed by ColN
at 600 mpc at 120 s. Negative control of ColNΔTolA added at 2 × 105 mpc (black).
B. ColNOBS1 (solid red line) was added at 600 mpc at 120 s as an unblocked control. For all other runs ColNΔTolA was added at 2 × 105 mpc at
60 s followed by either ColNOBS1 (red open circles), ColNF14G (open blue circles), ColNH10G (open orange circles) or ColN(41–387) (open magenta
circles) at 600 mpc at 120 s. Negative control to which no colicin is added to cells (black).
C. ColN (solid green line) and ColNF14G (solid blue line) were added at 600 mpc at 120 s as unblocked controls. For all other blocking runs
ColN-RP was added at 2 × 105 mpc at 0 s followed by ColN (green open circles) or ColNF14G (blue open circles) at 600 mpc at 120 s. Negative
control to which no colicin is added to cells (black solid line). ColN-RP added at 2 × 105 mpc at 0 s (solid cyan line).
D. ColN (solid green line), ColNOBS1 (solid red line) and ColN(41–387) (solid magenta line) were added at 600 mpc at 120 s as unblocked controls.
For all other blocking runs ColN-RP was added at 2 × 105 mpc at 0 s followed by either ColNOBS1 (red open circles) or ColN(41–387) (magenta
open circles) at 120 s. Negative control to which no colicin is added to cells (black solid line), ColN-RP added at 2 × 105 mpc at 0 s (solid cyan
line).
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Thus either the P-domain in TP is assisting the docking of
T-domain to the OmpF or, if it is forming pores in the
cytoplasmic membrane, its activity is very much reduced.
Post-translational modification of ColN-T under
prolonged induction conditions
To increase the yield of ColN-T purification (typically
0.5 mg l−1) induction times were increased from 2 h to 16 h.
Surprisingly, although yields of pure protein increased
significantly, the antibacterial activity was often low or zero
and these samples did not behave as a protein with a pI of
9.3. In cation exchange chromatography using 20 mM
potassium phosphate, pH 7.5, 150 mM NaCl as the
loading buffer, ∼ 90% of ColN-T loaded onto the column did
not bind. This fraction was inactive whereas the ColN-T
which bound and was then eluted from the column as
normal behaved as ColN-T produced under 2 h induction
conditions.
Given the structure of ColN-T, the most likely cause is the
deamidation of asparagine residues in Asn–Gly pairs, pro-
ducing either aspartate or iso-aspartate (Robinson et al.,
2001). To test this hypothesis two mutants were made
which changed Asn–Gly pairs to Ser–Gly; ColN-T(N4S)
and ColN-T(N53S) (Fig. 3A). ColN-T(N4S) was consistently
active when produced using a 16 h induction protocol while
ColN-T(N53S) was not. This indicates that deamidation of N4
was the cause of inactivity. N4 is just upstream of our
tentative OBS1 site (8–15 aa) (Fig. 3A) and so introduction
of a negatively charged aspartic/isoaspartic acid residue at
this position may disrupt OmpF binding. All data presented
here used T-domain produced by short induction times and
Fig. 5. ColN-T shows no evidence of interaction with model membranes.
A. Tryptophan fluorescence. Buffer (20 mM Tris-HCl, pH 7.5, 300 mM NaCl) (black) or E. coli lipid liposomes composed of natural E. coli
phospholipids (red) were mixed with ColN-T (25 μg ml−1) and fluorescence emission spectra recorded from 300 to 450 nm.
B. Circular dichroism analysis to compare the secondary structure of ColN-T in 10 mM sodium phosphate pH 7.5, 150 mM NaCl (black) and
10 mM NaP pH 7.5, 150 mM NaCl, 1 mM SDS (red).
C. K+ efflux assay to determine if ColN-T can cause K+ leakage from K+ loaded liposomes. K+ loaded liposomes were added at 0 s followed by
ColN-T at 1 μM (blue), melittin at 1 μM (green) or 10 μM (red) at 60 s. To assess the basal leakage from K+ loaded liposomes a negative
control was carried out where nothing was added to the liposomes (black).
Fig. 6. Comparing ColN-TR and ColN-TP activities.
A. Self-inhibition of killing using ColN-TR. A comparison of the rate of K+ efflux induced by ColN-T and ColN-TR when added at 104, 5 × 104,
105, 2 × 105 and 6 × 105 mpc. The rate of efflux was calculated from the linear region of the efflux curve. The rate of efflux induced by ColN-T
increases with multiplicity while ColN-TR has a maximal rate when added at 105 mpc.
B. K+ efflux induced by ColN-TP, ColN-TR and ColN-T at 2.5 × 104 mpc. ColN-TP (orange line), ColN-TR (red line) and ColN-T (blue line)
were added at 2.5 × 104 mpc at 0 s. ColN (green) added at 600 mpc at 0 s is shown for reference. Negative control to which no colicin is
added to cells (black solid line).
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a full analysis of the post-translational modifications of
ColN-T will be published elsewhere.
Discussion
Truncation of an E. coli antibiotic reveals hidden
antimicrobial activity of an intrinsically unfolded domain
It is a longstanding core dogma of colicin biology that the
C-terminal cytotoxic domains of colicins are indispensable
for bactericidal activity. Thus the retention of antibacterial
toxicity when this domain is removed was entirely unex-
pected. Colicins are outstandingly efficient killers so even
though ColN-T is four orders of magnitude less efficient
than ColN, its MIC (10 μM) is still comparable to other
AMPs. Furthermore, removal of both the R-domain and
C-terminal cytotoxic domain results in a protein (ColN-T)
which has an MIC (10 μM) still comparable to known
AMPs (Melo et al., 2009). We have therefore shown that
amino acids 1–69 define the minimal killing unit of ColN
and may correlate with an original bacteriocin from which
the full-length colicin developed. Acquisition of R-domain
would have afforded a significant evolutionary advantage
through its improved efficiency (μM to nM MIC) and finally
recruitment of a dedicated pore-forming domain would
generate the highly efficient three-domain ColN we know
today. If this is the case, and it is notable that all colicins
do possess an unstructured T-domain, the retention of
antimicrobial activity in ColN-T after this time is remark-
able. There is no evidence yet of this activity in other
colicin IUDs, Colicin Ia T-domain is protective (Jakes and
Finkelstein, 2010) while point mutations in the active sites
of enzymatic colicins abolish toxicity (Garinot-Schneider
et al., 1996)
Loss of OBS1 can be tolerated in full-length ColN but
not in ColN-T/ColN-TR
Within this relatively small IUD reside a TolA binding site
and the newly identified OmpF binding site. Just like full-
length ColN, both receptors were subsequently shown to
be essential for ColN-T and ColN-TR toxicity. However
one clear difference between ColN-T/ColN-TR and their
full-length counterpart is their absolute requirement of
OBS1 for activity. ColNOBS1 induced K+ efflux which was
only modestly different from ColN; however, ColN-TROBS1
and ColN-TOBS1 were completely inactive. For ColE9 in
which two OBS have been identified, the presence of at
least one OBS is vital for cytotoxicity (Housden et al.,
2011). ColN, which has a much shorter T-domain than
ColE9, only has one OBS and its loss can be tolerated in
vivo. Presumably in ColNOBS1, which only shows a small
change in MIC (supplementary data), the RP domains
compensate for the loss of OmpF binding in the T-domain
(Clifton et al., 2012). R-domain does bind to OmpF in vitro
in the absence of detergent (Evans et al., 1996b; Stora
et al., 1999) and the self-inhibition seen here implies that
there is competition between the T and R domains for
OmpF. It is very easy to block OBS mutants if one pre-
treats the cells with ColN TolA-box mutants which cannot
fully translocate. These possibly stay attached to OmpF
and cannot be displaced by OBS mutants. Thus OBS
binding may be a very early step in toxicity but the role
that OBS plays in the physiological activity of full-length
ColN and other colicins is not yet clear.
ColN-T shares similarities with microcins and does not
kill by membrane disruption
Killing bacteria by membrane disruption is very effective
and small pore-forming AMPs have been suggested as
new generation antibiotics. However the target of most
AMPs, the lipid bilayer, is common to animals and bacte-
ria, making selective bacterial toxicity a demanding goal.
Here, ColN-T is unusual in that, although its apparent site
of action is the inner membrane, it binds not lipid but
specific protein targets. The release of K+ ions may be
symptomatic of other membrane effects (Csonka and
Hanson, 1991) but the rapid kinetics argue for a direct
physical rather than chemical target. The size of ColN-T
shares some similarities with the microcins but unlike
ColN-T these generally hijack the Ton system. The 88
residue colicin V, now renamed microcin V was reported
to abolish membrane potential but interestingly pore-
formation could not be observed in liposomes (Yang
and Konisky, 1984). Interestingly, remnants of the ColV
operon exist in pAPEC-O1-ColBM, a plasmid encoding
colicins B and M, hinting that ColBM-type plasmids may
have evolved from ColV plasmids (Johnson et al., 2006).
Thus, ColN-T is the first example of an antimicrobial
protein which combines a natively unfolded structure with
targeted membrane permeabilization. OmpF and TolA
homologues are widely found in Gram-negative bacterial
pathogens making this killing mechanism a tangible target
for the development of small molecules with low MICs
suitable for antibacterial drug therapy (Strom et al., 2003;
Gillor et al., 2004).
ColN-TR self-inhibition suggests ColN may hijack two
OmpF molecules in the outer membrane
Colicin self-inhibition has been demonstrated before by
Jakes and Finkelstein (2010). When performing the
spot test assay using high concentrations of ColIa they
observed zones of inhibition with a clear periphery but
turbid centres. Furthermore, the same self-inhibition was
detected in liquid culture, with ColIa found to kill more
efficiently at ∼ 170 mpc than at 8700 mpc. The basis of
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self-inhibition is that a single ColIa molecule binds two
separate Cir proteins (~ 5000 copies per cell) (Konisky
and Cowell, 1972) via its R- and T-domains respectively.
Self-inhibition at high concentrations is due to binding of
the high-affinity R-domain to every copy of Cir on the cell
which prevents the essential binding of the lower affinity
T-domain. ColN-TR self-inhibition occurs at multiplicities
exceeding 105 mpc suggesting that the R-domain of
ColN-TR binds OmpF which is present at ∼ 105 copies per
cell and inhibits T-domain killing (Sodergren et al., 1985).
Jakes and Finkelstein (2010) demonstrated self-inhibition
using full-length ColIa, but we see no self-inhibition with
full-length ColN and only with Col-TR. Thus self-inhibition
implies that both colicins Ia and N use two copies of their
Omp receptor. In the case of ColN one interaction, OBS,
can be deleted and it is interesting that Colicin S4 has two
identical receptor (OmpW)-binding domains of which only
one needs to be functional for toxicity (Arnold et al.,
2009).
Experimental procedures
Bacterial strains
The standard strain used for assaying colicin killing is
BE3000 (OmpC−). To check for OmpF and TolA dependence
of colicin activity the strains BZB1107 (OmpC−, OmpF−,
LamB−) and JC207 (TolA−) were used respectively. To screen
for TolQ and R dependence of colicin activity we used the
Keio parental strain BW25113 [rrnB3 ΔlacZ4787 hsdR514
Δ(araBAD)567 Δ(rhaBAD)568], ΔtolQ (tolQ786::kan) and
ΔtolR (tolR787::kan).
Constructs used in this work
DNA sequences encoding the constructs used in this work
were synthesized by GeneArt (Regensburg, Germany). In
addition to encoding the colicin constructs in the forward
frame the cognate colicin N immunity protein was encoded in
the reverse frame. All GeneArt DNA sequences were synthe-
sized with a C-terminal –SSHHHHHH tag with NdeI (5′)
and BamHI (3′) restriction sites for subcloning into pET3a
(Novagen).
Protein purification
OmpF was purified as described previously (Lakey et al.,
1985), precipitated in cold ethanol and resuspended in
20 mm sodium phosphate, pH 7.2, 300 mM NaCl, 1% (v/v)
octyl-polyoxyethylene (POE) (Enzo). EDTA was then added
to the OmpF solution to a final concentration of 10 mM before
loading (0.5 mg ml−1) onto a size exclusion column (Superose
12) equilibrated 20 mm sodium phosphate buffer, pH 7.2,
300 mM NaCl, 10 mM EDTA, 1% (v/v) octyl-polyoxyethylene
(POE) (Enzo). All colicin constructs were purified as
described previously (Fridd et al., 2002), followed by dialysis
into 50 mm sodium phosphate, pH 7.6, 300 mm NaCl.
Spot test assay
Colicin domain mutants were assayed for activity using
the established spot test dilution assay (Pugsley and
Schnaitman, 1978).
K+ efflux assay using live cells
A single colony of E. coli BE3000 cells was used to inoculate
5 ml of 1× LB and grown overnight, shaking at 37°C. After 16 h
growth 1 ml of cells was used to inoculate 100 ml of 1× LB
supplemented with 10 mM KCL. Cells were grown by shaking
at 37°C, until an OD600 of 0.5–0.6. Cells were harvested by
centrifugation at 3000 g at 25°C for 15 min. The supernatant
was carefully discarded the cell pellet washed with 4× 1 ml
aliquots of 100 mM sodium phosphate, pH 7.0 (assay buffer)
before resuspension in 1 ml of 100 mM sodium phosphate,
pH 7.0, 5% glycerol (loaded assay buffer). Cells were stored
on ice and used within 3 h of preparation after allowing for
30 min equilibration on ice. Following equilibration a defined
aliquot containing 5 × 109 cells was taken and added to a
jacketed K+ efflux vessel maintained stirring at 37°C containing
6 ml of pre-warmed assay buffer. Data recording was started
upon addition of cells using an ion-selective K+ electrode,
double junction lithium acetate reference electrode and a
temperature probe. Upon addition to the vessel the cells
re-accumulate K+ over approximately 5 min until a stable
baseline is reached. Unless otherwise stated colicin was
added to the vessel 60 s after the cells had reached a stable
baseline. Data were normalized to zero at the point of colicin
addition and measurements continued for 7 min, with data
points being taken every 5 s. For all K+ efflux measurements
the basal rate of K+ loss from 5 × 109 cells was recorded to
serve as a negative control. The results shown are representa-
tive of a minimum of three independent experiments.
MICs
A single colony of E. coli BE3000 cells was added to 5 ml of
1× LB and grown overnight, shaking at 37°C. After 16 h
growth 1 ml of cells was used to inoculate 50 ml of 1× LB.
Cells were grown by shaking at 37°C, until an OD600 of 1.5. An
aliquot of cells was then diluted 1/100 with 1× LB and 5 μl of
diluted cells added to each well of a 96-well plate. Stocks of
100 μM and 1 nm of ColN domain mutants were prepared
in 1× LB and each of the stock solutions serially diluted
to produce a dilution series of 10 μM, 1 μM, 10 nM, 1 nM,
0.1 nM, 10 pM and 1 pM. MIC was scored as the lowest
concentration of a particular colicin domain mutant at which
no growth of the E. coli was observed after 18 h of incubation
while shaking at 37°C.
Preparation of K+ loaded liposomes
Fifty milligrams of E. coli natural lipid extract (Avanti) (57.5%
PE, 15.1% PG, 9.8% CA, 17.6% unknown) in chloroform was
dried and stored under vacuum for 3 h to remove remaining
solvent. Lipids were then resuspended in 5 ml of 100 mM
potassium phosphate pH 7.0 to give a 10 mg ml−1 stock. The
solution was then sonicated on ice for 20 min before centrifu-
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gation at 13 000 g for 30 min. The supernatant containing the
liposomes was exchanged for K+-free 100 mM sodium Phos-
phate pH 7.0 using a PD10 column.
Liposome efflux assay
ColN-T or melittin (positive control) were added 60 s after
liposome addition. Additional runs were carried out where
liposomes alone (negative control) were added to the vessel
to assess basal K+ leakage from the vesicles. Data were
normalized to zero at the point of liposome addition and
measurements typically continued for ∼ 15 min, with data
points being taken every 5 s.
Tryptophan fluorescence
Tryptophan fluorescence emission spectra were measured
with a Varian spectrofluorimeter (Varian, USA) using a
280 nm excitation wavelength. Slits were set at 5 nm for
excitation and emission. Emission spectra were recorded
between 300 and 450 nm with a scan rate of 600 nm min−1 in
a 0.5 cm pathlength cuvette at 25°C. Spectra in the presence
of liposomes were corrected for light scattering by subtracting
the corresponding liposome background. Under each condi-
tion four spectra were averaged.
Circular dichroism
Circular dichroism was measured using a J-810 spectropo-
larimeter (Jasco, Japan) and Quartz-Suprasil circular cell
(Hellma, GmbH & Co., Germany). The far-UV spectrum was
recorded over 10 accumulations between 190 and 260 nm
before averaging the data. Processing of the spectra included
subtracting the buffer spectrum from the sample spectrum
before conversion into standard units of Δε (M−1 cm−1).
Isothermal titration calorimetry (ITC)
ITC measurements were performed using a MicroCal ITC200
thermostatted at 25°C, with all protein samples prepared in
20 mM K+ phosphate, pH 7.5, 150 mM NaCl, 1% Octyl-poe.
OmpF was present in the sample cell at a concentration of
40–50 μM per monomer with the colicin concentration in the
syringe varying from 400 to 700 μM. Binding isotherms were
analysed using the manufacturer’s software.
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